A Phase III Trial to Compare ETC vs, EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN).

Trial Profile

A Phase III Trial to Compare ETC vs, EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN).

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Ibandronic acid (Primary) ; Capecitabine; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Early breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GAIN
  • Most Recent Events

    • 12 Dec 2015 Results of retrospective analysis presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 16 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2013 Primary endpoint 'Disease-free-survival' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top